To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Patient compliance with a… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women.

Journal article
Authors J D Ringe
G E Christodoulakos
Dan Mellström
H Petto
T Nickelsen
F Marín
I Pavo
Published in Current medical research and opinion
Volume 23
Issue 11
Pages 2677-87
ISSN 1473-4877
Publication year 2007
Published at Institute of Medicine, School of Public Health and Community Medicine
Pages 2677-87
Language en
Links informahealthcare.com/doi/abs/10.11...
Keywords Alendronate, administration & dosage, therapeutic use, Drug Administration Schedule, Etidronic Acid, administration & dosage, analogs & derivatives, therapeutic use, Female, Humans, Middle Aged, Osteoporosis, drug therapy, Patient Compliance, Postmenopause, Prospective Studies, Raloxifene, administration & dosage, therapeutic use
Subject categories Endocrinology

Abstract

OBJECTIVES: The aim was to investigate patient compliance with different osteoporosis medications commonly prescribed in clinical practice, to determine risk factors associated with discontinuation and to evaluate quality of life changes. RESEARCH DESIGN AND METHODS: We conducted a 1-year observational study of patients of age > or = 60 years in a clinical setting at 917 sites in 10 European countries (Germany, Greece, UK, Sweden, Netherlands, Romania, Norway, Finland, Denmark, Estonia), Lebanon and South Africa. Demographic data, concomitant diseases, the reasons for intervention, educational, socio-economical status and disease knowledge were captured at baseline. Self-reported compliance, discontinuation data and health status were collected. MAIN OUTCOME MEASURES: Out of 5198 patients, 3490 (67.1%) patients received 60 mg daily raloxifene (RAL), 452 (8.7%) 10 mg daily alendronate (AQD), 769 (14.8%) 70 mg once weekly alendronate (AQW) and 487 (9.4%) 5 mg daily risedronate (RIS). Among patients completing the study (4231, 81%), the percentage of patients with high compliance was 80% (RAL), 79% (AQD), 65% (AQW) and 76% (RIS). The discontinuation due to side effects was highest on AQW (7.0%), followed by AQD (6.4%), RAL (3.8%) and RIS (3.4%). The discontinuation-rate was higher for patients with a history of surgical menopause, increased age, lack of knowledge about medical prevention of osteoporosis and thin frame as a reason for intervention. The EQ-5D weighted index showed the highest improvement for RIS (0.13), followed by RAL (0.11), AQD (0.08) and AQW (0.07). CONCLUSIONS: Data from this non-interventional observational study indicate moderate overall compliance and discontinuation rate with the prescribed osteoporosis medications.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?